Katja S Håheim1, Emil Lindbäck1, Kah Ni Tan2, Marte Albrigtsen3, Ida T Urdal Helgeland1, Clémence Lauga1, Théodora Matringe1, Emily K Kennedy2, Jeanette H Andersen3, Vicky M Avery2,4,5, Magne O Sydnes1. 1. Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, NO-4036 Stavanger, Norway. 2. Discovery Biology, Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan, QLD 4111, Australia. 3. The Norwegian College of Fishery Science, Marbio, UiT-The Arctic University of Norway, Breivika, NO-9037 Tromsø, Norway. 4. CRC for Cancer Therapeutics, Griffith University, Nathan, QLD 4111, Australia. 5. School of Environment & Science, Nathan, Griffith University, Nathan, QLD 4111, Australia.
Abstract
A series of novel quinoline-based tetracyclic ring-systems were synthesized and evaluated in vitro for their antiplasmodial, antiproliferative and antimicrobial activities. The novel hydroiodide salts 10 and 21 showed the most promising antiplasmodial inhibition, with compound 10 displaying higher selectivity than the employed standards. The antiproliferative assay revealed novel pyridophenanthridine 4b to be significantly more active against human prostate cancer (IC50 = 24 nM) than Puromycin (IC50 = 270 nM) and Doxorubicin (IC50 = 830 nM), which are used for clinical treatment. Pyridocarbazoles 9 was also moderately effective against all the employed cancer cell lines and moreover showed excellent biofilm inhibition (9a: MBIC = 100 µM; 9b: MBIC = 100 µM).
A series of novel quinoline-based tetracyclic ring-systems were synthesized and evaluated in vitro for their antiplasmodial, antiproliferative and antimicrobial activities. The novel n class="Chemical">hydroiodide salts 10 and 21 showed the most promising antiplasmodial inhibition, with compound 10 displaying higher selectivity than the employed standards. The antiproliferative assay revealed novel pyridophenanthridine 4b to be significantly more active against human prostate cancer (IC50 = 24 nM) than Puromycin (IC50 = 270 nM) and Doxorubicin (IC50 = 830 nM), which are used for clinical treatment. Pyridocarbazoles 9 was also moderately effective against all the employed cancer cell lines and moreover showed excellent biofilm inhibition (9a: MBIC = 100 µM; 9b: MBIC = 100 µM).
Authors: L Dassonneville; A Lansiaux; A Wattelet; N Wattez; C Mahieu; S Van Miert; L Pieters; C Bailly Journal: Eur J Pharmacol Date: 2000-12-01 Impact factor: 4.432
Authors: K Bonjean; M C De Pauw-Gillet; M P Defresne; P Colson; C Houssier; L Dassonneville; C Bailly; R Greimers; C Wright; J Quetin-Leclercq; M Tits; L Angenot Journal: Biochemistry Date: 1998-04-14 Impact factor: 3.162
Authors: Caroline H Johnson; Christine M Dejea; David Edler; Linh T Hoang; Antonio F Santidrian; Brunhilde H Felding; Julijana Ivanisevic; Kevin Cho; Elizabeth C Wick; Elizabeth M Hechenbleikner; Winnie Uritboonthai; Laura Goetz; Robert A Casero; Drew M Pardoll; James R White; Gary J Patti; Cynthia L Sears; Gary Siuzdak Journal: Cell Metab Date: 2015-05-07 Impact factor: 27.287
Authors: K Cimanga; T De Bruyne; L Pieters; J Totte; L Tona; K Kambu; D V Berghe; A J Vlietinck Journal: Phytomedicine Date: 1998-05 Impact factor: 5.340
Authors: Christopher Wittmann; Felix Bacher; Eva A Enyedy; Orsolya Dömötör; Gabriella Spengler; Christian Madejski; Jóhannes Reynisson; Vladimir B Arion Journal: J Med Chem Date: 2022-02-01 Impact factor: 7.446